Scleroderma-like cutaneous sclerosis has been reported as a rare adverse reaction to several drugs, including the chemotherapeutical agent paclitaxel, used in therapeutic regimens for several malignancies. The sclerosis is usually limited to the skin, most commonly presenting in the lower limbs after weeks to months of therapy but is often refractory to treatment and progresses even after discontinuation of the offending agents, with significant resulting morbidity. We report a rare case of severe cutaneous sclerosis secondary to chemotherapy with nab-paclitaxel and gemcitabine, which did not respond to treatment and led to discontinuation of chemotherapy.
No takes yet. Share an insight, caveat, or question.
Flor et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: